Navigation Links
Intarcia Therapeutics Appoints Gino Santini To Its Board Of Directors
Date:7/26/2013

f the company's Executive Committee, Mr. Santini led corporate strategy and long-range planning, M&A, new product licensing, innovative financing of internal development projects, and the expansion of Lilly Ventures in the U.S. and China. In addition to Intarcia, Mr. Santini serves on the Boards of Directors of several other biopharmaceutical companies and an Italian financial holding company. Fluent in four languages, Mr. Santini holds an undergraduate degree in mechanical engineering from the University of Bologna, and an MBA from the Simon School of Business, University of Rochester.

Mr. Santini explained that his enthusiasm for joining the Intarcia Board is prompted most by the Company's potential opportunity to make a real difference in the lives of patients with type 2 diabetes:  "This is truly an exciting time in the evolution of Intarcia, and quite possibly in the future management of type 2 diabetes. I believe Intarcia has thoughtfully put together the handful of critical ingredients for major success: a differentiated and potentially game-changing lead product candidate, world-class scientific, manufacturing and business competencies, a strong Board and top-tier investors, and a proven team full of passion to outperform the marketplace and help patients. I look forward to working with the Board and senior leadership to help guide the company to the full measure of success possible."

About ITCA 650
ITCA 650 (a once- or twice-yearly continuous subcutaneous delivery of exenatide) is being developed for the treatment of type 2 diabetes. The investigational therapy employs Intarcia's proprietary technology platform involving a matchstick-size, miniature osmotic pump (minipump) that is inserted subcutaneously to provide continuous and consistent drug therapy, and the company's proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for exte
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intarcia Appoints Owen Hughes Chief Business Officer and Head of Corporate Development
2. Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
3. Intarcia Supports American Diabetes Association Call For Independent Review Of Incretin-Based Therapies
4. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
6. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
9. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
10. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... UNION CITY, Calif. , Nov. 21, 2014 /PRNewswire/ ... products company manufacturing point-of-care instruments and consumables for the ... lab services to the veterinary and research markets in ... the completion of a stock purchase agreement to acquire ... United Kingdom based distribution organization. The ...
(Date:11/21/2014)... 21, 2014 Clementia Pharmaceuticals, ... Agency (EMA) has granted Orphan Medicinal Product ... candidate, for the treatment of fibrodysplasia ossificans ... disabling genetic disease characterized by painful, recurrent ... new abnormal bone formation. This process, known ...
(Date:11/21/2014)... YORK , Nov. 20, 2014  Market research firm ... the "Year of The Buy, in the medical device ... for medical devices will produce just 3% growth this ... actions, including acquisitions of product lines and entrance by ... annual survey of medical devices, The Global Market ...
Breaking Medicine Technology:Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3Kalorama: 2014 The "Year of The Buy" in Medical Device Industry 2
... NEW YORK, Sept. 12, 2011 A revolutionary new ... other technology - - the VivoSight® Optical Coherence ... to dermatologists in the U.S. for the first time. ... skin surface instantly, providing additional information which will allow ...
... Sept. 12, 2011 Intarcia Therapeutics, Inc. announced ... ITCA 650 (DUROS® subcutaneous continuous delivery of exenatide) ... the 47th Annual Meeting of the European Association ...  All three presentations are scheduled for Wednesday, September ...
Cached Medicine Technology:Revolutionary Device for Use in Detecting Non-Melanoma Skin Cancer in Real Time, Alleviates Patient Stress, Can Reduce Invasive Biopsy 2Revolutionary Device for Use in Detecting Non-Melanoma Skin Cancer in Real Time, Alleviates Patient Stress, Can Reduce Invasive Biopsy 3Revolutionary Device for Use in Detecting Non-Melanoma Skin Cancer in Real Time, Alleviates Patient Stress, Can Reduce Invasive Biopsy 4Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes 2Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes 3Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes 4
(Date:11/23/2014)... OH (PRWEB) November 23, 2014 Syngenta ... LLC on behalf of farmers and agribusinesses that have ... attempts to commercialize Agrisure Viptera and Agrisure Duracade, ... not been approved for sale in China. According to ... China to virtually ban U.S. corn imports. Because China ...
(Date:11/22/2014)... Greenville, Sc (PRWEB) November 23, 2014 ... officially opened its doors in the downtown Greenville area. ... of Downtown Greenville , decided to open her own ... such amazing results with the patients. , AlignLife ... the proper tools. With a focus on chiropractic care ...
(Date:11/22/2014)... 2014 Recently, Locks-Magnetic.com , one ... new promotion of mag locks for glass doors online. ... discount on these fresh products. Customers can get more ... glass doors are in excellent performance. Customers who want ... as soon as possible. They also can enjoy ...
(Date:11/22/2014)... Discount-Dress.com is an important company in ... to increase the company’s online market share by a series ... bridesmaid dresses and announced a bridesmaid dress promotion for the ... 30, 2014. All the dresses from this company are not ... fact, Discount-Dress.com is very good at manufacturing wedding dresses. Customers ...
(Date:11/22/2014)... Domestic farmgate milk and dairy solids ... to a fall in demand for Butter ... the global financial crisis. However, these declines did ... manufacturers on the international scene. Strong growth in ... primarily due to supply constraints in some key ...
Breaking Medicine News(10 mins):Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 2Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 3Health News:AlignLife of Downtown Greenville is Now Open and Accepting New Patients 2Health News:Discounted Mag Locks for Glass Doors Revealed by Locks-Magnetic.com 2Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4
... added to standard therapy appears to offer a survival advantage ... of brain cancer, according to a study from researchers at ... Anderson Cancer Center. The vaccine also knocks out a ... the disease. "About a third of all glioblastomas are ...
... Total Health, a unique benefits program for Group Health Cooperative ... federal Agency for Health Research and Quality (AHRQ) recently funded. ... wellness programs and base them on research findings. The goal ... costs. Launched in January 2010 and available to all ...
... Md., October 4, 2010 As the Medicare Model ... Medicare Part D plans can utilize when developing their ... the U.S. Pharmacopeial Convention (USP) is announcing its revision ... it develops Version 5.0. Medicare Model Guidelines ...
... By Jenifer Goodwin HealthDay Reporter , ... of parents with health insurance say they haven,t gotten ... new survey in Ohio finds. Parents of kids ... those with public health insurance such as Medicaid or ...
... Medical Center,s Reinberger Neuroscience Intensive Care Unit (NSU) has ... This is a top honor from the American Association ... The NSU joins four other intensive care units ... been recognized with Beacon Awards: Medical Intensive Care ...
... cassava ( Manihot esculenta ) serve as the primary ... many arid regions of the world, including more than ... roots of commercial cassava cultivars are quite low in ... In addition to programs designed to deliver vitamin ...
Cached Medicine News:Health News:Duke vaccine extends survival for patients with deadly brain cancers 2Health News:Duke vaccine extends survival for patients with deadly brain cancers 3Health News:Incentives studied to align care, coverage and wellness 2Health News:Incentives studied to align care, coverage and wellness 3Health News:New Medicare model guidelines for benefit years 2012-2014 in development 2Health News:Many Kids Not Getting Recommended Care: Survey 2Health News:Many Kids Not Getting Recommended Care: Survey 3Health News:University Hospitals Case Medical Center's neuroscience intensive care unit earns Beacon Award 2Health News:Using cassava to address vitamin A deficiency 2
... Parachute Tissue Anchor allows one step fixation of ... for arthroscopic knotless rotator cuff repair in one ... an outside thread diameter of 5 mm and ... FiberWire suspension sutures securely hold a thin, bioabsorbable ...
... The Bio-SutureTak is a 3 mm bioabsorbable ... ideal for soft tissue attachment to bone in ... small anchor profile with high pull-out strength is ... molded into the body of the anchor and ...
TigerStick is a white #2 FiberStick with black stripes and a stiffened, 12 inch, waxed end. It is especially useful when motion determination and alternating colored sutures are required in the arthr...
... MMS soon offers the Flowmaster. It is ... everyday flow studies, where ease of use, simplicity ... wireless uroflowmeter which makes it now very easy ... the flowmaster anywhere you want and data will ...
Medicine Products: